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Abstract A series of novel Schiff bases and secondary
amines were obtained in good yields, as a result of the
reductive amination of alkyl 2-(2-formyl-4-nitrophe-
noxy)alkanoates with both aniline and 4-methoxyaniline
under established mild reaction conditions. Sodium tri-
acetoxyborohydride as well as hydrogen in the presence of
palladium on carbon were used as efficient reducing agents
of the Schiff bases, in both direct and stepwise reductive
amination processes. The Schiff bases, amines, and
amine hydrochlorides were designed as potential antibac-
terial agents, and structure–activity relationship could be
established following in vitro assays against Gram-positive
and Gram-negative bacteria. The minimal inhibitory con-
centration and zone of inhibition were also determined. In
these tests, some of Schiff bases and secondary amine
hydrochlorides showed moderate-to-good activity against
Gram-positive bacteria, including S. aureus, M. luteus, and
S. mutans.
Keywords Amines  Antibacterial activities  Esters 
2-(2-Formylphenoxy)alkanoic acids  Reduction 
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Introduction
The major problem in the effective antibacterial treatment
is increasing resistance of microorganisms to currently
available antimicrobial drugs. Therefore, the development
of novel antimicrobial drugs is an active area of research.
Most of compounds bearing an azomethine group exhibit
antimicrobial (da Silva et al., 2011; Mohini et al., 2013;
Shi et al., 2007), antioxidant, and antiproliferative prop-
erties (Cheng et al., 2010). Schiff bases, such as nitrofu-
rantoin or nifuroxazide, are commonly applied in medicine
as antibacterial agents (Sztanke et al., 2013). Additionally,
a variety of phenoxyalkanoic acid derivatives are also
known to possess a wide range of bioactivities (Hullar and
Failla, 1969; Pattan et al., 2009; Kumar and Kumaresan,
2012), and some of the Schiff bases derived from
2-formylphenoxyacetic acids exhibit antibacterial proper-
ties (Bala et al., 2010; Iqbal et al., 2007). Further, aromatic
secondary amines, as well as their salts, are also known to
possess antimicrobial activity (Kitahara et al., 2004; Singh
et al., 2011). Finally, secondary amines containing an
aromatic nitro group exhibit an arginase inhibitory effect
on vascular smooth muscle cell proliferation (Curtis et al.,
2013).
A widely useful method for the synthesis of amines is
reductive amination, which involves the reaction of alde-
hydes and ketones with ammonia or primary/secondary
amines in the presence of a selective reducing agent
(Tarasevich and Kozlov, 1999; Gomez et al., 2002). This
process is considered direct when a carbonyl compound
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and an amine are mixed together with a reducing agent in a
single operation. On the other hand, a stepwise reductive
amination involves the pre-formation of the intermediate
imine, followed by reduction in a separate step (Abdel-
Magid et al., 1996). A wide variety of reducing agents have
been utilized for reductive amination; however, two
methods have been used most commonly. The first method
involves catalytic hydrogenation with platinum, palladium,
ruthenium, cobalt or nickel catalysts (Klyuev and Khide-
kel, 1980; Petrisko and Krupka, 2005; Tripathi et al.,
2008). The second method utilizes metal hydride reagents,
mainly sodium borohydride (Panfilov et al., 2000), sodium
triacetoxyborohydride (Abdel-Magid and Mehrman, 2006;
Gribble, 2006), sodium or lithium cyanoborohydride
(Borch et al., 1971; Grenga et al., 2009), and sodium
borohydride modified with numerous polyvalent metal salts
(Saxena et al., 2000; Saidi et al., 2007; Neidigh, et al.,
1998) or activated by acids (Cho and Kang, 2005; Ali-
nezhad et al., 2010).
Here, we report the synthesis of a series of Schiff bases
and amines that were designed as potential antimicrobial
agents. The synthesis involves the chemoselective reaction
of primary amines with alkyl 2-(2-formyl-4-nitrophe-
noxy)alkanoates yielding Schiff bases bearing intact the
ester group, as well as further reduction of the Schiff bases
to the corresponding amino esters. Further, we have per-
formed antibacterial screening of the obtained compounds
against Gram-positive and Gram-negative bacteria and
analyzed the influence of the electron-donating substituents
such as methoxyl and amino groups in the phenyl rings, as




The desired alkyl 2-(2-formylphenoxy)alkanoates 1a–g
were obtained in high yield by the condensation of
adequately substituted 2-hydroxybenzaldehydes with alkyl
2-bromoalkanoates in the presence of potassium bicar-
bonate in dimethylformamide (Kwiecien´, 2004). The
Schiff bases 3a–l were prepared by the reaction of alkyl
2-(2-formylphenoxy)alkanoates 1a–g with aniline (2a) and
4-methoxyaniline (2b) (Scheme 1). To determine the
optimal conditions of the process, a series of reactions of
methyl 2-(2-formyl-4-nitrophenoxy)butanoate (1a) with
aniline (2a) were carried out using different solvents, such
as tetrahydrofuran, 1,2-dichloroethane, and methanol or
without any solvent. The influence of the ratio of reagents,
reaction time, and catalyst on the yield was also assessed,
as indicated in Table 1.
Based on these studies, we found that a nearly quanti-
tative yield of the desired product was obtained when the
reaction was carried out in methanol and in the presence of
catalytic amount of the acetic acid, using equimolar ratio of
the reactants (Entry 7, Table 1).
Under these established conditions, the reaction pro-
ceeded chemoselectively in the formyl group and leaving
unchanged the ester group. Importantly, it was observed
that the product 3a could be obtained in high yield by using
an aprotic solvent, such as 1,2-dichloroethane in the pres-
ence of catalytic amounts of acetic acid. This is important
for the direct reductive amination, which is more effective
when it is carried out in 1,2-dichloroethane, as demon-
strated later. The Schiff base was separated from the
reaction mixture by dilution with water, followed by fil-
tration of the precipitate.
Next, the Schiff bases 3b–l were readily prepared by
reactions of formyl esters 1b–g with aniline (2a) and
4-methoxyaniline (2b), in the established reaction condi-
tions (1:1 molar ratio of the formyl ester to amine,
methanol as solvent, catalytic amount of acetic acid, room
temperature, 3.5 h). The crude products (3b–l) were crys-
tallized from methanol to yield stable crystals with high
melting points (mp); yield: 72–95 %. Some of the Schiff
bases exhibit a wide range of their melting points (see
experimental section) that is probably caused by presence
of (E-) and (Z-) diastereoisomers in the solid state of the
products.
The structures of novel Schiff bases 3a–l were con-
firmed by gas chromatography mass spectrometry
(GCMS), Fourier transform infrared spectroscopy (FTIR),
and 1H and 13C nuclear magnetic resonance (NMR). The
infrared spectra exhibited an intense absorption band in the
range of 1623–1614 cm-1, characteristic of the azomethine
groups. Additionally, intense bands, originating from the
valence vibrations of the ester carbonyl group, were
observed in the range 1756–1733 cm-1 (C=O stretch) and
1208–1198 cm-1 (C–O stretch). Further, we observed a
singlet of integration intensity equivalent to one hydrogen
at 9.10–8.94 ppm in the 1H NMR spectra of the Schiff
bases, indicating the presence of the azomethine proton
(–CH=N–).
Two methods were used for the reduction of Schiff
bases. The first one was carried out using sodium triace-
toxyborohydride (STAB) as a selective reducing agent of
the imino group only and giving nitro amines 4a–
f (Scheme 2). The second method consisted of catalytic
reduction of both imino and nitro groups, resulting in the
formation of diamine compounds 5a, c–f (Scheme 3).
To determine the optimal conditions for the reduction of
Schiff bases with sodium triacetoxyborohydride to the nitro
amines 4a–f, a series of reactions was carried out, starting
from model compound 3a and using the following solvents:
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methanol, 1,2-dichloroethane, tetrahydrofuran, and N,N-
dimethylformamide (Table 2). Utilizing methanol resulted
in a low yield of amino ester, and neither extending the
reaction time nor increasing the temperature improved the
yield. Similarly, low yield was obtained using N,N-
dimethylformamide in the presence of catalytic amounts of
acetic acid. The best result was obtained using a 1:1.5
molar ratio of Schiff base/STAB in 1,2-dichloroethane and
a catalytic amount of acetic acid. The reaction was carried
out at room temperature for 4 h. Next, the reaction mixture
was neutralized with 5 % aqueous solution of sodium
bicarbonate, and the organic layer was separated and dried
using magnesium sulfate. The product was isolated by
solvent removal under reduced pressure and was recrys-
tallized from methanol, to yield pure amino ester 4a. Under
these optimal conditions, the synthesis of compounds 4b-
f was readily achieved with moderate-to-good yields
(Scheme 2). All of the synthesized amino esters 4a–f are
novel compounds. Their structures were established by
spectroscopic methods: GC–MS, FTIR, 1H, and 13C NMR.
The FTIR spectra exhibited an intense absorption band in
























1, 3 R R1 R2 R3
Yield of 3 
(%)
3 R R1 R2 R3
Yield of 3 
(%)
a H H Et Me 95 g H OMe H2 Et 90
b H H n-Pr Me 76 h OMe H Et Me 83
c H H n-Bu Me 89 i OMe H n-Bu Me 72
d H OMe Et Me 85 j OMe OMe Et Me 89
e H OMe n-Pr Me 85 k OMe OMe n-Pr Me 90
f H OMe n-Bu Me 78 l OMe OMe n-Bu Me 76
Scheme 1 Synthesis of Schiff bases from formyl esters 1a–g and aniline (2a) or 4-methoxyaniline (2b)
Table 1 Synthesis of methyl 2-(4-nitro-2-((phenylimino)methyl)phenoxy)butanoate (3a)
Entry 1a/2a ratio (mmol/mmol) Solvent (mL) Reaction time (h) Yielda (%)
1 1/1 THF 12 24 91
2 1/1 THF/MeOH 6/6 5.5 93
3 1/1 DCE 8 24 56
4 1/1 DCEb 8 24 91
5 1/1.5 DCEb 8 24 92
6 1.5/1.5 DCE/MeOH 4/4 72 62
7 1/1 MeOHb 6 3.5 99
8 1/1 – – 24 77c
a Yield based on GC analysis of the reaction mixture
b Catalytic amount of acetic acid was added
c Reaction was carried out without any solvent
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groups. Additionally, intense bands, originating from the
valence vibrations of the ester carbonyl group, were
observed in the range 1751–1742 cm-1 (C=O stretch) and
1209–1200 cm-1 (C–O stretch). In the 1H NMR spectra of
the amino esters, the multiplet at 4.70–4.31 ppm is consist
of two doublets and broad signal which are derived from
two protons of CH2 and a one proton of NH group,
respectively. The deuterium exchange experiment with
D2O was performed to confirm the presence of amine
proton (see Supporting Information).
Reduction of both nitro and azomethine groups of 3a
and 3c–f was carried out in mild conditions: in methanol
with the addition of dimethoxyethane (DME), using a 1:0.1
weight ratio of Schiff base to catalyst, 10 % Pd/C



















3, 4 R1 R2 Yield of 4 (%) 3, 4 R1 R2 Yield of 4 (%)
a H Et 60 d OMe Et 55
b H n-Pr 60 e OMe n-Pr 55
c H n-Bu 55 f OMe n-Bu 85
Scheme 2 Reduction of Schiff





















3, 5 R1 R2 3, 5 R1 R2
a H Et e OMe n-Pr
c H n-Bu f OMe n-Bu
d OMe Et
Scheme 3 Catalytic reduction of Schiff bases 5a and 5c–f
Table 2 Reduction of Schiff base 3a to amine 4a with STAB
Entry 4a/STAB ratio (mmol/mmol) Solvent (mL) Reaction temp. Reaction time (h) Yielda (%)
1 1/1.4 DMFc 14 100 C 5 21
2 1/1.4 MeOH 44 rt 3 23
3 1/1.4 MeOH 44 reflux 4 27
4 1/1.4 THF 20 reflux 4 65
5 1/1.7 DCE 20 rt 6 86
6 1/1.5 DCEb 17 rt 4 93
7 1/2.0 DCEb 17 rt 4 81
8 1/1.5 DCEc 17 rt 4 84
a Yield based on GC analysis of reaction mixture
b Added AcOH (0.1 mL)
c Added AcOH (0.2 mL)
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products 5a and 5c–f were obtained after removing of the
solvent under vacuum. Diamines 5a, c–f were obtained as
brown semi-solids, in good yield (71–86 %, Table 3).
The FTIR spectra of 5a, c–f exhibit an intensive
absorption band in the range of 3410–3374 cm-1, charac-
teristic of the amine groups. Additionally, intensive bands,
originating from the valence vibrations of the ester carbonyl
group, were observed in the range 1735–1737 cm-1.
Finally, the signal at 9.10–8.94 ppm in the 1H NMR spectra,
associated with azomethine group, disappeared and instead
signals at ranges 3.90–3.53 and 1.51–0.78 ppm were
observed, indicating the presence of the amine protons.
Subsequently, reductive amination of methyl 2-(2-
formylphenoxy)alkanoate 1a–f was investigated as a one-
step process. Synthesis of amines via direct reductive
amination is very useful, because it does not require iso-
lating the intermediate Schiff bases. This greatly speeds up
the process of synthesis and limits losses associated with
isolation of the intermediates.
To determine optimal conditions for the direct reductive
amination, the model formyl ester 1a was reacted with
aniline (2a) in the presence of sodium triacetoxyborohy-
dride as the reducing agent. The reactions were conducted
at ambient temperature, using different solvents, and
changing the molar ratio of the reactants and reaction times
(Table 4).
The highest yield of the desired product was achieved
when the reaction was performed in 1,2-dichloroethane
with a catalytic amount of acetic acid for 4 h, with an
equimolar ratio of formyl ester and aniline and 1.5 mol
excess of the catalyst.
The direct reductive amination of 1b–f was carried out
using the same conditions as for 1a, resulting in good
yields (71–85 %) of amines 4b–f (Scheme 4). Finally,
amino esters 4a–f were converted into their hydrochloride
salts.
Microbiology
All of the synthesized compounds were screened for
antibacterial activity against selected clinically important
Gram-positive (S. aureus, M. luteus, S. mutans, E. faecalis)
and Gram-negative (E. coli, P. aeruginosa, A. baumannii)
bacteria by the disk diffusion method. Acetone was used as
solvent for Schiff bases, and DMSO as solvent for amines
and hydrochloride salts of amines. The antibiotic cipro-
floxacin (5 mg/mL) was used as a positive control. The
results of antibacterial screening indicate that four of ele-
ven tested Schiff bases 3a, 3c–e exhibit varied activity
against Gram-positive bacteria, including S. aureus, and S.
mutans. The bacterial inhibition zone values of the Schiff
bases are summarized in Table 5.
Table 3 Catalytic reduction of Schiff bases 3a and 3c–f with hydrogen
3 3/(10 % Pd/C) ratio (g/g) MeOH (mL) DME (mL) 5 Yield (%)
a 0.31/0.031 40 10 a 85
c 0.20/0.020 35 7 c 82
d 0.20/0.020 35 20 d 71
e 0.36/0.036 40 10 e 84
f 0.16/0.016 35 7 f 74
Table 4 Synthesis of 4a via the direct reductive amination of methyl 2-(2-formyl-4-nitrophenoxy)butanoate (1a)
1a/2a/STAB ratio (mmol/mmol/mmol) Solvent (mL) Catalyst Reaction time (h) Yielda (%)
1/1/1 THF – 50 42
1/1/1.45 THF – 50 61
1/1/1 DCE – 50 91
1/1.5/1.5 DCE – 50 98
1/1/1.5 DCE – 4 59
1/1/1.5 DCE – 24 86
1/1/1.5 DCE Amberlyst-15 4 89
1/1/1.5 DCE AcOH 4 98
a Yield based on GC analysis
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Schiff base 3d exhibited antibacterial activity only
against S. aureus strains and caused the strongest inhibition
of the growth of methicillin-resistant S. aureus. Schiff base
3a, on the other hand, caused the strongest inhibition of the
growth of S. mutans. It should also be mentioned that the
synthesized Schiff bases did not inhibit the growth of
E. faecalis and M. luteus. Further, introducing the meth-
oxyl group into Schiff base structure has a significant
impact on antibacterial activity. No antibacterial activity
was observed for the Schiff bases containing methoxyl in
N-substituted phenyl ring (3h–l, R=OMe). Likewise, the
presence of methoxyl group at 2-position in 3d structure
abolishes activity against S. mutans, in contrast to S.
aureus, where activity increases against MRSA. Increas-
ing alkyl, hydrophobic chain length results in decreased
antibacterial activity, except for the influence of 3e on
S. mutans.
Followed the screening, the minimum inhibitory con-
centration (MIC) was determined for the Schiff bases that
demonstrated activity against specific species of bacteria.
The results are presented in Table 6.
Next, it was observed that amino esters 4a-f did not show
any antimicrobial activity, while their hydrochlorides
showed good inhibition of the Gram-positive bacteria
(Table 7). The most active were those without the methoxyl





















1, 4 R1 R2 Yield of 4 (%) 1, 4 R1 R2 Yield of 4 (%)
a H Et 85 d OMe Et 84
b H n-Pr 82 e OMe n-Pr 78
c H n-Bu 71 f OMe n-Bu 74
Scheme 4 Direct reductive
amination of formyl esters 1a–
f to 4a–f
Table 5 Antibacterial activitya of the Schiff bases 3a and 3c–e at 10 mg/mL concentration
Compound S. aureus S. mutans
MSSA ATCC 25923 MRSA ATCC 43300 MLSB clinical isolate clinical isolate
3a 13 8 9 10
3c 7 7 8 7
3d 10 15 12 –
3e 8 13 13 7
ciprofloxacin 25 26 27 28
a Zone of inhibition in mm; ‘–’ means not sensitive (no antimicrobial activity was recorded)
Table 6 Minimum inhibitory concentration (MIC, mg/mL) of Schiff bases 3a, c–e
Compound S. aureus S. mutans
MSSA ATCC 25923 MRSA ATCC 43300 MLSB clinical isolate clinical isolate
3a 0.10 0.10 0.10 0.50
3c 0.50 0.25 0.25 0.50
3d 0.25 0.25 0.25 1.00
3e 0.25 0.10 0.10 1.00
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antibacterial activity was observed. The lack of inhibition for
amino esters might be caused by the presence of an
intramolecular hydrogen bond that can be formed between
amino proton and carbonyl group in the amino esters.
The broadest spectrum of antibacterial activity was
noted for 4cHCl. This compound inhibited the growth of
all Gram-positive bacteria and was the only compound
synthesized in these studies that inhibited the growth of the
Gram-negative A. baumannii. The MIC of hydrochloride
salts of 4a–f is given in Table 8.
Three other hydrochloride salts of amino esters, 4aHCl,
4bHCl, 4fHCl, inhibited the growth of all Gram-positive
bacteria, having MICs of 0.50–1.00, 0.05–1.0, and
0.01–0.25 mg/mL, respectively, for each bacterial strain.
Moderate antibacterial activity was also recorded for 4eHCl,
which inhibited the growth of E. faecalis and M. luteus. The
most encouraging results against Gram-positive bacteria were
obtained for compounds 4cHCl and 4fHCl having MICs of
0.05–0.50 and 0.01–0.25 mg/mL, respectively.
The structure–activity relationships of the tested com-
pounds can be summarized as follows: (1) in series of the
Schiff bases, the presence of methoxyl group at the N-
phenyl ring has a significant negative impact on their
antibacterial activity; (2) in the same series, elongation of
hydrophobic, alkyl chain causes the decrease in antibac-
terial activity against S. aureus MSSA and MRSA; (3)
reduction of azomethine group to amine causes loss of
activity against all of the tested microorganism; (4) in
series of amine hydrochlorides, the presence of methoxyl
group at the N-phenyl ring has the same negative impact on
their antibacterial activity as in the case of Schiff bases;
opposite effect is observed for elongation of hydrophobic,
alkyl chain that causes the increase in antibacterial activity.
Lack of activity of the tested substances against Gram-
negative bacteria could be explained by the differences in
the structure of the cell walls of Gram-positive and Gram-
negative microorganisms. In most Gram-positive bacteria,
the cell wall consists of many layers of peptidoglycan,
forming a thick, rigid structure. The cell walls of Gram-
negative bacteria consist of one or a very few layers of
peptidoglycan and a lipid-rich outer membrane (Beveridge,
1999). However, the mechanism responsible for the
antibacterial activity of examined compounds is not known
at the moment; work is in progress to clarify in detail the
mechanism of antibacterial action, as well as the design of
more effective compounds.
Conclusion
We demonstrate simple and efficient methods for both
stepwise and direct reductive amination of 2-(2-formyl-4-
nitrophenoxy)alkanoic acid derivatives, yielding secondary
N-arylated amines via Schiff bases under mild conditions.
Table 7 Antibacterial activitya of amino esters 4a–f at 10 mg/mL concentration
Compound E. faecalis S. aureus M. luteus S. mutans
ATCC 29212 MSSA ATCC 25923 MRSA ATCC 43300 MLSB clinical isolate PCM 1944 clinical isolate
4aHCl 12 8 – 8 15 11
4bHCl 12 12 7 7 14 14
4cHCl 17 16 13 8 17 21
4eHCl 8 – – – 8 –
4fHCl 13 13 14 12 15 15
ciprofloxacin 20 25 26 27 22 28
a Zone of inhibition in mm; ‘–’ no antimicrobial activity was recorded
Table 8 Minimum inhibitory concentration (MIC, mg/mL) of hydrochloride salts of the amino esters 4a–f
Gram-positive
E. faecalis S. aureus M. luteus S. mutans
ATCC 29212 MSSA ATCC 25923 MRSA ATCC 43300 MLSB clinical isolate PCM 1944 clinical isolate
4aHCl 0.50 0.50 NT 1.00 0.50 0.50
4bHCl 0.25 0.10 0.50 1.00 0.05 0.25
4cHCl 0.05 0.10 0.25 0.50 0.05 0.10
4eHCl 0.50 NT NT NT 1.00 NT
4fHCl 0.05 0.01 0.25 0.25 0.05 0.10
NT means not tested
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The reduction step was performed utilizing sodium tri-
acetoxyborohydride, as well as catalytic hydrogenation
using palladium(0) catalyst. Our antibacterial screening
assay indicates that some of Schiff bases and secondary
amine hydrochlorides possess moderate-to-good activity
against Gram-positive bacteria, including S. aureus, M.
luteus, and S. mutans. In a series of Schiff bases, we
observe some of the influence of chain length and presence
of methoxyl group on the antibacterial activity. Further
modification of the selected compounds based on the
information obtained from these results, as well as
molecular modeling and structure–activity relationship
studies, are in progress.
Materials and methods
Chemistry
1H and 13C NMR spectra were recorded on a TM Bruker
DPX 400 (400 MHz) instrument, with CDCl3 solvent.
Chemical shifts d are given from TMS (0 ppm), as an
internal standard for 1H NMR, and CDCl3 (77.0 ppm), for
13C NMR (100 MHz). Mass spectra were obtained using an
Agilent Technologies 6890 N apparatus, equipped with a
mass detector 5973 Network and 30 m 9 0.25 mm capil-
lary column, filled with a 0.25-lm film of 5 % MePh sil-
icate. Fourier transform infrared-attenuated total reflection
spectroscopy (FTIR–ATR) was performed using a Nexus
spectrometer with Golden Gate (ATR) (Thermo Nicolet
Corp.). Samples were dried at 60 C, under vacuum for
24 h, and 32 scans were averaged across the spectral range
of 400–4000 cm-1. All melting points were determined
using a Boetius apparatus and are uncorrected.
Most of the reagents and solvents were purchased in
commercially available grade purity. 2-Hydroxy-3-meth-
oxy-5-nitrobenzaldehyde (mp 140–142 C) and 2-hydroxy-
5-nitrobenzaldehyde (mp 129–131 C) were obtained by
nitration of appropriate 2-hydroxy-3-methoxybenzalde-
hyde or 2-hydroxybenzaldehyde with 100 % nitric acid in
acetic acid solution (Kwiecien´ and Szychowska, 2007),
although they are commercially available. Methyl 2-(2-
formyl-4-nitrophenoxy)alkanoates 1a–c were prepared
starting from appropriate 2-bromoesters and 2-hydroxy-5-
nitrobenzaldehyde according to the literature (Kwiecien´,
2004). Methyl 2-(2-formyl-6-methoxy-4-nitrophenoxy)
alkanoates 1d–f and ethyl 2-formyl-6-methoxy-4-nitro-
phenoxy)acetate 1g were obtained starting from 2-hydroxy-
3-methoxy-5-nitrobenzaldehyde and appropriate 2-bro-
moesters according to procedures in Kwiecien´ (2004) and
Kwiecien´ and Szychowska (2007), respectively (Fig. 1).
General procedure for the synthesis of methyl 2-(4-
nitro-2-((phenylimino)methyl)phenoxy)alkanoate
(3a–l)
A mixture of alkyl 2-(2-formyl-4-nitrophenoxy)alkanoate
(1a–g) (1.87 mmol), aniline (2a) or p-methoxyaniline (2b)
(1.87 mmol), methanol (50 mL), and acetic acid (0.2 mL)
was stirred magnetically at room temperature for 3.5 h.
Then, the reaction mixture was poured into water (27 mL)
and allowed to stand at 5–7 C (in a refrigerator) for 24 h.
The precipitate was filtered off, washed with water, and
recrystallized from hot methanol to give 3a–l.
Methyl 2-(4-nitro-2-((phenylimino)methyl)phenoxy)bu-
tanoate (3a) Colorless solid (MeOH) This compound
(3a) was prepared from methyl 2-(2-formyl-4-nitrophe-
noxy)butanoate (1a) (1.87 mmol, 0.50 g) and aniline (2a)
(1.87 mmol, 0.17 g) according to the general procedure.
The product obtained as a colorless solid was purified from
methanol. 0.61 g (95 %); mp 111–117 C; FTIR (neat)
mmax: 3081, 2975, 1744, 1620, 1585, 1510, 1340, 1210,
1077 cm-1; 1H NMR (CDCl3, 400 MHz): d = 9.09 (d,
J = 2.9 Hz, 1H, Ar), 8.95 (s, 1H, N=CH), 8.27 (dd,
J = 2.9, 9.1 Hz, 1H, Ar), 7.49–7.38 (m, 2H, Ar), 7.30–7.24
(m, 3H, Ar), 6.86 (d, J = 9.1 Hz, 1H, Ar), 4.83 (t,
J = 6.0 Hz, 1H, CH), 3.78 (s, 3H, OCH3), 2.18–2.05 (m,


































































Fig. 1 Numbering for 13C
NMR spectra
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(CDCl3, 101 MHz): d = 170.5 (C, C-2), 161.7 (CH, C-12),
153.4 (C, C-5), 151.6 (C, C-13), 142.4 (C, C-8), 129.3 (C,
C-15, C-17), 127.4 (C, C-7), 126.6 (C, C-9), 126.2 (C,
C-10), 124.0 (C, C-16), 121.1 (C, C-14, C-18), 112.5 (C,
C-6), 78.4 (CH, C-3), 52.6 (OCH3, C-1), 26.0 (CH2CH3,
C-4), 9.7 (CH2CH3, C-4); GCMS m/z 342 [M]
? (32), 327
(9), 283 (32), 250 (18), 225 (18), 222 (5), 195 (23), 190 (8),
179 (7), 175 (100), 145 (23), 139 (7), 104 (17), 93 (22), 77
(48), 59 (29), 51 (8); Anal. Calcd for C18H18N2O5: C,
63.15; H, 5.30; N, 8.18. Found: 63.12; H, 5.40; N, 8.15.
Methyl 2-(4-nitro-2-((phenylimino)methyl)phenoxy)pen-
tanoate (3b) Colorless solid (MeOH) This compound
(3b) was prepared from methyl 2-(2-formyl-4-nitrophe-
noxy)pentanoate (1b) (1.78 mmol, 0.50 g) and aniline (2a)
(1.78 mmol, 0.162 g) according to the general procedure.
The product obtained as a colorless solid was purified from
methanol. 0.48 g (76 %); mp 84–87 C; FTIR (neat) mmax:
3102, 2962, 1733, 1614, 1579, 1515, 1341, 1268,
1078 cm-1; 1H NMR (CDCl3, 400 MHz): d = 9.10 (d,
J = 2.9 Hz, 1H, Ar), 8.94 (s, 1H, N=CH), 8.28 (dd,
J = 2.9, 9.1 Hz, 1H, Ar), 7.47–7.41 (m, 2H, Ar), 7.32–7.25
(m, 3H, Ar), 6.87 (d, J = 9.1 Hz, 1H, Ar), 4.88 (dd,
J = 4.9, 7.6 Hz, 1 H, CH), 3.79 (s, 3H, OCH3), 2.14–1.98
(m, 2H, CH2), 1.65–1.50 (m, 2H, CH2), 1.01 (t,
J = 7.4 Hz, 3H, CH3);
13C NMR (CDCl3, 101 MHz):
d = 170.7 (C, C-2), 161.7 (CH, C-12), 153.5 (C, C-5),
151.6 (C, C-13), 142.3 (C, C-8), 129.2 (C, C-15, C-17),
127.4 (C, C-7), 126.6 (C, C-9), 126.1 (C, C-10), 124.0 (C,
C-16), 121.1 (C, C-14, C-18), 112.5 (C, C-6), 77.2 (CH,
C-3), 52.6 (OCH3, C-1), 34.5 (CH2CH2CH3, C-4), 18.6
(CH2CH2CH3, C-4), 13.7 (CH2CH2CH3, C-4); GCMS m/z
356 [M]? (55), 327 (55), 297 (32), 264 (23), 241 (16), 225
(20), 204 (9), 195 (29), 189 (100), 179 (7), 167 (19), 145
(12), 130 (5), 118 (5), 104 (16), 93 (29), 77 (42), 59 (19);
Anal. Calcd for C19H20N2O5: C, 64.04; H, 5.66; N, 7.86.
Found: C, 64.14; H, 5.68; N, 7.82.
Methyl 2-(4-nitro-2-((phenylimino)methyl)phenoxy)hex-
anoate (3c) Colorless solid (MeOH) This compound (3c)
was prepared from methyl 2-(2-formyl-4-nitrophe-
noxy)hexanoate (1c) (1.69 mmol, 0.50 g) and aniline (2a)
(1.69 mmol, 0.154 g) according to the general procedure.
The product obtained as a colorless solid was purified from
methanol. 0.56 g (89 %); mp 68–71 C; FTIR (neat) mmax:
3088, 2956, 1737, 1611, 1579, 1510, 1339, 1203,
1072 cm-1; 1H NMR (CDCl3, 400 MHz): d = 9.09 (d,
J = 2.9 Hz, 1H, Ar), 8.94 (s, 1H, N=CH), 8.27 (dd,
J = 2.9, 9.1 Hz, 1H, Ar), 7.46–7.40 (m, 2H, Ar), 7.31–7.25
(m, 3H, Ar), 6.86 (d, J = 9.1 Hz, 1H, Ar), 4.86 (t,
J = 6.2 Hz, 1H, CH), 3.78 (s, 3H, OCH3), 2.15–2.00 (m,
2H, CH2), 1.57–1.46 (m, 2H, CH2), 1.46–1.35 (m, 2H,
CH2), 0.94 (t, J = 7.2 Hz, 3H, CH3);
13C NMR (CDCl3,
101 MHz): d = 170.7 (C, C-2), 161.7 (CH, C-12), 153.5
(C, C-5), 151.6 (C, C-13), 142.4 (C, C-8), 129.3 (C, C-15,
C-17), 127.4 (C, C-7), 126.6 (C, C-9), 126.1 (C, C-10),
124.0 (C, C-16), 121.1 (C, C-14, C-18), 112.5 (C, C-6),
77.4 (CH, C-3), 52.7 (OCH3, C-1), 32.2 (CH2CH2CH2CH3,
C-4), 27.3 (CH2CH2CH2CH3, C-4), 22.2 (CH2CH2CH2-
CH3, C-4), 13.9 (CH2CH2CH2CH3, C-4); GCMS m/z 370
[M]? (51), 327 (52), 311 (31), 295 (6), 278 (24), 242 (27),
225 (21), 203 (100), 195 (32), 188 (10), 167 (21), 145 (10),
104 (17), 93 (40), 77 (46), 59 (20); Anal. Calcd for
C20H22N2O5: C, 64.85; H, 5.99; N, 7.56. Found: C, 64.80;
H, 5.64; N, 7.83.
Methyl 2-(2-methoxy-4-nitro-6-((phenylimino)methyl)phe-
noxy)butanoate (3d) Colorless solid (MeOH) This com-
pound (3d) was prepared from methyl 2-(2-formyl-
6-methoxy-4-nitrophenoxy)butanoate (1d) (1.68 mmol,
0.50 g) and aniline (2a) (1.68 mmol, 0.153 g) according to
the general procedure. The product obtained as a colorless
solid was purified from methanol. 0.53 g (85 %); mp
124-129 C; FTIR (neat) mmax: 3088, 2977, 1746, 1619,
1577, 1518, 1341, 1202, 1085 cm-1; 1H NMR (CDCl3,
400 MHz): d = 9.09 (s, 1H, N=CH), 8.74 (d, J = 2.9 Hz,
1H, Ar), 7.83 (d, J = 2.9 Hz, 1H, Ar), 7.46–7.39 (m, 2H,
Ar), 7.33–7.24 (m, 3H, Ar), 5.13 (dd, J = 5.4, 6.9, 1H,
CH), 3.96 (s, 3H, OCH3), 3.69 (s, 3H, OCH3), 2.13–1.97
(m, 2H, CH2), 1.11 (t, J = 7.6 Hz, 3H, CH3);
13C NMR
(CDCl3, 101 MHz): d = 171.4 (C, C-2), 155.0 (C, C-12),
152.0 (C, C-5), 151.7 (C, C-6), 151.6 (C, C-13), 143.7 (C,
C-8), 130.2 (C, C-10), 129.2 (C, C-15, C-17), 126.5 (C,
C-16), 121.2 (C, C-14, C-18), 115.6 (C, C-9), 108.9 (C,
C-7), 81.4 (CH, C-3), 56.4 (OCH3, C-11), 52.1 (OCH3,
C-1), 26.5 (CH2CH3, C-4), 9.4 (CH2CH3, C-4); GCMS m/z
372 [M]? (61), 357 (11), 313 (34), 280 (37), 280 (37), 271
(15), 255 (22), 252 (7), 236 (12), 225 (22), 210 (8), 205
(100), 196 (12), 190 (29), 175 (45), 154 (25), 127 (6), 104
(16), 93 (19), 77 (38), 59 (23), 51 (6); Anal. Calcd for
C19H20N2O6: C, 61.28; H, 5.41; N, 7.52. Found: C, 61.24;
H, 5.39; N, 7.55.
Methyl 2-(2-methoxy-4-nitro-6-((phenylimino)methyl)phe-
noxy)pentanoate (3e) Colorless solid (MeOH) This
compound (3e) was prepared from methyl 2-(2-formyl-6-
methoxy-4-nitrophenoxy)pentanoate (1e) (1.61 mmol,
0.50 g) and aniline (2a) (1.62 mmol, 0.147 g) according to
the general procedure. The product obtained as a colorless
solid was purified from methanol. 0.53 g (85 %); mp
126–128 C; FTIR (neat) mmax: 3086, 2961, 1745, 1623,
1575, 1517, 1328, 1205, 1071 cm-1; 1H NMR (CDCl3,
400 MHz): d = 9.08 (s, 1H, N=CH), 8.74 (d, J = 2.7 Hz,
1H, Ar), 7.83 (d, J = 2.7 Hz, 1H, Ar), 7.45–7.39 (m, 2H,
Ar), 7.45–7.39 (m, 3H, Ar), 5.19 (dd, J = 5.6, 6.7 Hz, 1H,
CH), 3.96 (s, 3H, OCH3), 3.67 (s, 3H, OCH3), 2.06–1.91
(m, 2H, CH2), 1.65–1.51 (m, 2H, CH2), 1.00 (t,
J = 7.4 Hz, 3H, CH3);
13C NMR (CDCl3, 101 MHz):
Med Chem Res (2015) 24:3561–3577 3569
123
d = 171.6 (C, C-2), 155.1 (C, C-12), 152.0 (C, C-5), 151.7
(C, C-6), 151.6 (C, C-13), 143.7 (C, C-8), 130.2 (C, C-10),
129.2 (C, C-15, C-17), 126.5 (C, C-16), 121.2 (C, C-14,
C-18), 115.6 (C, C-9), 108.8 (C, C-7), 80.1 (CH, C-3), 56.4
(OCH3, C-11), 52.1 (OCH3, C-1), 35.2 (CH2CH2CH3,
C-4), 18.3 (CH2CH2CH3, C-4), 13.7 (CH2CH2CH3, C-4);
GCMS m/z 386 [M]? (52), 357 (34), 327 (23), 297 (8), 294
(36), 271 (16), 255 (23), 235 (13), 219 (100), 204 (25), 189
(36), 175 (15), 154 (27), 127 (7), 104 (18), 93 (32), 77 (42),
59 (20); Anal. Calcd for C20H22N2O6: C, 62.17; H, 5.74; N,
7.25. Found: C, 62.47; H, 5.70; N, 7.30.
Methyl 2-(2-methoxy-4-nitro-6-((phenylimino)methyl)phe-
noxy)hexanoate (3f) Colorless solid (MeOH) This com-
pound (3f) was prepared from methyl 2-(2-formyl-6-
methoxy-4-nitrophenoxy)hexanoate (1f) (1.54 mmol,
0.50 g) and aniline (2a) (1.54 mmol, 0.14 g) according to
the general procedure. The product obtained as a colorless
solid was purified from methanol. 0.48 g (78 %); mp
82–91 C; FTIR (neat) mmax: 3090, 2953, 1744, 1619, 1575,
1525, 1322, 1200, 1091 cm-1; 1H NMR (CDCl3,
400 MHz): d = 9.08 (s, 1H, N=CH), 8.74 (d, J = 2.7 Hz,
1H, Ar), 7.83 (d, J = 2.7 Hz, 1H, Ar), 7.46–7.39 (m, 2H,
Ar), 7.33–7.24 (m, 3H, Ar), 5.17 (t, J = 6.1 Hz, 1H, CH),
3.96 (s, 3H, OCH3), 3.68 (s, 3H, OCH3), 2.06–1.96 (m, 2H,
CH2), 1.58–1.46 (m, 2H, CH2), 1.45–1.34 (m, 2H, CH2),
0.93 (t, J = 7.3 Hz, 3H, CH3);
13C NMR (CDCl3,
101 MHz): d = 171.6 (C, C-2), 155.2 (C, C-12), 152.0 (C,
C-5), 151.7 (C, C-6), 151.6 (C, C-13), 143.7 (C, C-8),
130.2 (C, C-10), 129.2 (C, C-15, C-17), 126.5 (C, C-16),
121.2 (C, C-14, C-18), 115.5 (C, C-9), 108.8 (C, C-7), 80.3
(CH, C-3), 56.4 (OCH3, C-11), 52.1 (OCH3, C-1), 32.9
(CH2CH2CH2CH3, C-4), 27.1 (CH2CH2CH2CH3, C-4),
22.4 (CH2CH2CH2CH3, C-4), 13.9 (CH2CH2CH2CH3,
C-4); GCMS m/z 400 [M]? (67), 369 (5), 357 (43), 341
(29), 308 (43), 297 (7), 276 (6), 271 (19), 255 (25), 248
(10), 233 (100), 226 (9), 210 (8), 203 (36), 196 (14), 180
(14), 154 (27), 127 (6), 104 (16), 93 (33), 77 (36), 69 (14);
Anal. Calcd for C21H24N2O6: C, 62.99; H, 6.04; N, 7.00.
Found: C, 63.10; H, 6.01; N, 6.97.
Ethyl 2-(2-methoxy-4-nitro-6-((phenylimino)methyl)phe-
noxy)acetate (3g) Colorless solid (MeOH) This com-
pound (3 g) was prepared from ethyl 2-(2-formyl-4-nitro-
phenoxy)acetate (1 g) (1.77 mmol, 0.50 g) and aniline (2a)
(1.77 mmol, 0.161 g) according to the general procedure.
The product obtained as an aquamarine solid was purified
from methanol. 0.57 g (90 %); mp 98–101 C; FTIR (neat)
mmax: 3107, 2944, 1756, 1617, 1577, 1516, 1337,
1199 cm-1; 1H NMR (CDCl3, 400 MHz): d = 9.10 (s, 1H,
N=CH), 8.74 (d, J = 2.6 Hz, 1H, Ar), 7.85 (d, J = 2.6 Hz,
1H, Ar), 7.45–7.38 (m, 2H, Ar), 7.34–7.23 (m, 3H, Ar),
4.91 (s, 2H, CH2), 4.22 (q, J = 7.1 Hz, 2H, OCH2), 3.99 (s,
3H, OCH3),1.24 (t, J = 7.1 Hz, 3H, CH3);
13C NMR
(CDCl3, 101 MHz): d = 168.8 (C, C-2), 154.8 (CH, C-12),
152.2 (C, C-5), 151.8 (C, C-6), 151.4 (C, C-13), 144.0 (C,
C-8), 130.1 (C, C-10), 129.2 (C, C-15, C-17), 126.6 (C,
C-16), 121.3 (C, C-14, C-18), 115.4 (C, C-9), 108.9 (C,
C-7), 69.5 (CH2, C-3), 61.4 (OCH2CH3, C-1), 56.5 (OCH3,
C-11), 14.1 (OCH2CH3, C-1); GCMS m/z 358 [M]
? (19),
329 (3), 285 (52), 255 (6), 239 (16), 225 (6), 210 (5), 194
(22), 179 (7), 167 (6), 148 (31), 104 (11), 93 (100), 77 (28),
61 (5). Anal. Calcd for C19H20N2O6: C, 61.28; H, 5.41; N,
7.52. Found: C, 61.32; H, 5.52; N, 7.50.
Methyl 2-(2-((4-methoxyphenylimino)methyl)-4-nitrophe-
noxy)butanoate (3h) Aquamarine solid (MeOH) This
compound (3 h) was prepared from methyl 2-(2-formyl-4-
nitrophenoxy)butanoate (1a) (1.69 mmol, 0.45 g) and p-
methoxyaniline (2b) (1.69 mmol, 0.205 g) according to the
general procedure. The product obtained as an aquamarine
solid was purified from methanol. 0.52 g (83 %); mp
108.5–110.5 C; FTIR (neat) mmax: 3090, 2932, 1737, 1615,
1596, 1510, 1342, 1214, 1075 cm-1; 1H NMR (CDCl3,
400 MHz): d = 9.08 (d, J = 2.9 Hz, 1H, Ar), 8.96 (s, 1H,
N=CH), 8.24 (dd, J = 2.9, 9.1 Hz, 1H, Ar), 7.33–7.28 (m,
2H, Ar), 6.99–6.94 (m, 2H, Ar), 6.84 (d, J = 9.1 Hz, 1H,
Ar), 4.82 (t, J = 6.0 Hz, 1H, CH), 3.85 (s, 3H, OCH3),
3.78 (s, 3H, OCH3), 2.12 (p, J = 7.4 Hz, 2H, CH2), 1.11 (t,
J = 7.4 Hz, 3H, CH3);
13C NMR (CDCl3, 101 MHz):
d = 170.5 (C, C-2), 161.5 (C, C-12), 158.8 (C, C-5), 151.0
(C, C-16), 144.3 (C, C-13), 142.3 (C, C-8), 127.0 (C, C-7),
126.4 (C, C-10), 123.6 (C, C-9), 122.6 (C, C-14, C-18),
114.4 (C, C-15, C-17), 112.5 (C, C-6), 78.3 (CH, C-3), 55.5
(OCH3, C-19), 52.6 (OCH3, C-1), 26.0 (CH2CH3, C-4), 9.6
(CH2CH3, C-4); GCMS m/z 372 [M]
? (100), 313 (16), 271
(9), 257 (12), 241 (11), 225 (16), 190 (5), 175 (54), 160 (7),
145 (14), 134 (7), 122 (60), 108 (7), 92 (10), 77 (10), 59
(14); Anal. Calcd for C19H20N2O6: C, 61.28; H, 5.41; N,
7.52. Found: C, 61.32; H, 5.52; N, 7.50.
Methyl 2-(2-((4-methoxyphenylimino)methyl)-4-nitrophe-
noxy)hexanoate (3i) Pale yellow solid (MeOH) This
compound (3i) was prepared from methyl 2-(2-formyl-4-
nitrophenoxy)hexanoate (1c) (1.69 mmol, 0.50 g) and p-
methoxyaniline (2b) (1.69 mmol, 0.208 g) according to the
general procedure. The product obtained as a pale yellow
solid was purified from methanol. 0.49 g (72 %); mp
102–104 C; FTIR (neat) mmax: 3090, 2927, 1739, 1616,
1592, 1516, 1333, 1198, 1080 cm-1; 1H NMR (CDCl3,
400 MHz): d = 9.08 (d, J = 2.9 Hz, 1H, Ar), 8.95 (s, 1H,
N=CH), 8.24 (dd, J = 2.9, 9.2 Hz, 1H, Ar), 7.33–7.28 (m,
2H, Ar), 6.99–6.93 (m, 2H, Ar), 6.84 (d, J = 9.2 Hz, 1H,
Ar), 4.85 (undivided dd, J = 5.6, 6.8 Hz, 1H, CH), 3.85 (s,
3H, OCH3), 3.78 (s, 3H, OCH3), 2.12–2.02 (m, 2H, CH2),
1.57–1.47 (m, 2H, CH2), 1.47–1.36 (m, 2H, CH2), 0.94 (t,
J = 7.2 Hz, 3H, CH3);
13C NMR (CDCl3, 101 MHz):
d = 170.8 (C, C-2), 161.5 (C, C-12), 158.8 (C, C-5), 151.1
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(C, C-16), 144.3 (C, C-13), 142.3 (C, C-8), 127.0 (C, C-7),
126.4 (C, C-10), 123.7 (C, C-9), 122.6 (C, C-14, C-18),
114.4 (C, C-15, C-17), 112.4 (C, C-6), 77.4 (CH, C-3), 55.5
(OCH3, C-19), 52.6 (OCH3, C-1), 32.2 (CH2CH2CH2CH3,
C-4), 27.3 (CH2CH2CH2CH3, C-4), 22.2 (CH2CH2CH2-
CH3, C-4), 13.9 (CH2CH2CH2CH3, C-4); GCMS m/z 400
[M]? (100), 357 (12), 341 (14), 297 (6), 272 (15), 257 (13),
241 (9), 225 (16), 203 (52), 182 (6), 173 (6), 154 (7), 145
(6), 134 (6), 122 (40), 108 (6), 92 (8), 77 (8), 59 (8); Anal.
Calcd for C21H24N2O6: C, 62.99; H, 6.04; N, 7.00. Found:
C, 62.96; H, 6.14; N, 7.02.
Methyl 2-(2-((4-methoxyphenylimino)methyl)-6-methoxy-4-
nitrophenoxy)butanoate (3j) Beige solid (MeOH) This
compound (3j) was prepared from methyl 2-(2-formyl-
6-methoxy-4-nitrophenoxy)butanoate (1d) (3.37 mmol,
1.00 g) and p-methoxyaniline (2b) (3.37 mmol, 0.415 g)
according to the general procedure. The product obtained
as a beige solid was purified from methanol. 1.20 g (89 %);
mp 116–117 C; FTIR (neat) mmax: 3099, 2948, 1746, 1619,
1577, 1518, 1341, 1202, 1091 cm-1; 1H NMR (CDCl3,
400 MHz): d = 9.10 (s, 1H, N=CH), 8.73 (d, J = 2.6 Hz,
1H, Ar), 7.80 (d, J = 2.6 Hz, 1H, Ar), 7.37–7.32 (m, 2H,
Ar), 7.00–6.93 (m, 2H, Ar), 5.10 (dd J = 5.6, 6.4 Hz, 1H,
CH), 3.95 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.69 (s, 3H,
OCH3), 2.14–1.98 (m, 2H, CH2), 1.11 (t, J = 7.5 Hz, 3H,
CH3);
13C NMR (CDCl3, 101 MHz): d = 171.4 (C, C-2),
158.8 (C, C-12), 152.6 (C, C-16), 151.7 (C, C-5, C-6),
144.3 (C, C-13), 143.7 (C, C-8), 130.5 (C, C-10), 122.7 (C,
C-14, C-18), 115.4 (C, C-9), 114.4 (C, C-15, C-17), 108.5
(C, C-7), 81.4 (CH, C-3), 56.4 (OCH3, C-11), 55.5 (OCH3,
C-19), 52.0 (OCH3, C-1), 26.5 (CH2CH3, C-4), 9.4 (CH2-
CH3, C-4); GCMS m/z 402 [M]
? (100), 343 (12), 301 (11),
281 (7), 271 (11), 255 (20), 236 (7), 221 (12), 205 (88), 190
(25), 175 (40), 162 (7), 134 (14), 122 (48), 108 (10), 92
(12), 77 (15), 59 (22); Anal. Calcd for C20H22N2O7: C,
59.70; H, 5.51; N, 6.96. Found: C, 59.82; H, 5.62; N, 6.76.
Methyl 2-(2-((4-methoxyphenylimino)methyl)-6-methoxy-4-
nitrophenoxy)pentanoate (3k) Pale yellow solid (MeOH)
This compound (3k) was prepared from methyl 2-(2-for-
myl-6-methoxy-4-nitrophenoxy)pentanoate (1e)
(3.22 mmol, 1.00 g) and p-methoxyaniline (2b)
(3.22 mmol, 0.396 g) according to the general procedure.
The product obtained as a pale yellow solid was purified
from methanol. 1.20 g (90 %); mp 105–106 C; FTIR
(neat) mmax: 3099, 2952, 1736, 1616, 1572, 1522, 1342,
1204, 1087 cm-1; 1H NMR (CDCl3, 400 MHz): d = 9.10
(s, 1H, N=CH), 8.73 (d, J = 2.5 Hz, 1H, Ar), 7.80 (d,
J = 2.6 Hz, 1H, Ar), 7.40–7.31 (m, 2H, Ar), 7.00–6.92 (m,
2H, Ar), 5.16 (undivided dd, J = 5.6, 6.8 Hz, 1H, CH),
3.95 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.67 (s, 3H,
OCH3), 2.09–1.90 (m, 2H, CH2), 1.71–1.46 (m, 2H, CH2),
1.00 (t, J = 7.4 Hz, 3H, CH3);
13C NMR (CDCl3,
101 MHz): d = 171.7 (C, C-2), 158.8 (C, C-12), 152.7 (C,
C-16), 151.7 (C, C-5, C-6), 144.3 (C, C-13), 143.7 (C,
C-8), 130.5 (C, C-10), 122.7 (C, C-14, C-18), 115.3 (C,
C-9), 114.4 (C, C-15, C-17), 108.4 (C, C-7), 80.1 (CH,
C-3), 56.3 (OCH3, C-11), 55.5 (OCH3, C-19), 52.1 (OCH3,
C-1), 35.2 (CH2CH2CH3, C-4), 18.3 (CH2CH2CH3, C-4),
13.8 (CH2CH2CH3, C-4); GCMS m/z 416 [M]
? (100), 387
(8), 357 (11), 301 (10), 285 (6), 271 (5), 255 (17), 235 (8),
219 (61), 204 (15), 189 (22), 184 (6), 175 (9), 134 (8), 122
(21), 108 (6), 92 (6), 77 (7), 59 (8); Anal. Calcd for
C21H24N2O7: C, 60.57; H, 5.81; N, 6.73. Found: C, 60.65;
H, 5.72; N, 6.73.
Methyl 2-(2-((4-methoxyphenylimino)methyl)-6-methoxy-4-
nitrophenoxy)hexanoate (3l) Aquamarine solid (MeOH)
This compound (3l) was prepared from methyl
2-(2-formyl-6-methoxy-4-nitrophenoxy)hexanoate (1f)
(3.08 mmol, 1.00 g) and p-methoxyaniline (2b) (3.08 mmol,
0.379 g) according to the general procedure. The product
obtained as an aquamarine solid was purified from
methanol. 1.32 g (76 %); mp 116–119 C; FTIR (neat)
mmax: 3102, 2955, 1739, 1616, 1592, 1516, 1333, 1198,
1092 cm-1; 1H NMR (CDCl3, 400 MHz): d = 9.10 (s, 1H,
N=CH), 8.72 (d, J = 2.3 Hz, 1H, Ar), 7.80 (d, J = 2.3 Hz,
1H, Ar), 7.37–7.32 (m, 2H, Ar), 6.99–6.93 (m, 2H, Ar),
5.13 (t, J = 6.0 Hz, 1H, CH), 3.95 (s, 3H, OCH3), 3.85 (s,
3H, OCH3), 3.68 (s, 3H, OCH3), 2.00 (p, J = 7.0 Hz, 2H,
CH2), 1.59–1.46 (m, 2H, CH2), 1.45–1.34 (m, 2H, CH2),
0.93 (t, J = 7.2 Hz, 3H, CH3);
13C NMR (CDCl3,
101 MHz): d = 171.6 (C, C-2), 158.8 (C, C-12), 152.7 (C,
C-16), 151.7 (C, C-5), 151.6 (C, C-6), 144.3 (C, C-13),
143.7 (C, C-8), 130.5 (C, C-10), 122.7 (C, C-14, C-18),
115.3 (C, C-9), 114.4 (C, C-15, C-17), 108.5 (C, C-7), 80.4
(CH, C-3), 56.3 (OCH3, C-11), 55.5 (OCH3, C-19), 52.1
(OCH3, C-1), 32.9 (CH2CH2CH2CH3, C-4), 27.1 (CH2-
CH2CH2CH3, C-4), 22.4 (CH2CH2CH2CH3, C-4), 13.9
(CH2CH2CH2CH3, C-4); GCMS m/z 430 [M]
? (100), 387
(8), 371 (11), 301 (10), 285 (6), 271 (5), 262 (2), 255 (17),
248 (5), 233 (59), 218 (12), 206 (7), 203 (23), 184 (6), 175
(7), 134 (8), 122 (20), 108 (6), 92 (6), 77 (7), 59 (7). Anal.
Calcd for C22H26N2O7: C, 61.39; H, 6.09; N, 6.51. Found:
C, 61.45; H, 6.20; N, 6.75.
General procedure for the synthesis of methyl 2-(4-
nitro-2-((phenylamino)methyl)phenoxy)alkanoate
(4a–f)
To a mixture of methyl 2-(4-nitro-2-((phenylimino)
methyl)phenoxy)alkanoate (3a–f) (0.58 mmol) in 1,2-
dichloroethane (10 mL), sodium triacetoxyborohydride
(0.88 mmol) and acetic acid (0.1 mL) were added. The
mixture was stirred magnetically at room temperature for
4 h. Then, the mixture was quenched with an aqueous
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solution of sodium carbonate 5 % (NaHCO3). The DCE
layer was separated and dried (MgSO4). The solvent was
removed under reduced pressure to give the crude product.
The resultant organic layer was dried, evaporated, and
residue was recrystallized from hot methanol, to yield 4a–f.
Methyl 2-(4-nitro-2-((phenylamino)methyl)phenoxy)bu-
tanoate (4a) Yellow solid (MeOH) This compound (4a)
was prepared from methyl 2-(4-nitro-2-((phenylim-
ino)methyl)phenoxy)butanoate (3a) (0.58 mmol, 0.20 g)
and sodium triacetoxyborohydride (0.88 mmol, 0.186 g)
according to the general procedure. The product obtained
as a yellow solid was purified from methanol. 0.12 g
(60 %); mp 106–108 C; FTIR (neat) mmax: 3406, 3075,
2979, 1750, 1593, 1330, 1204, 1085 cm-1; 1H NMR
(CDCl3, 400 MHz): d = 8.24 (d, J = 2.8 Hz, 1H, Ar),
8.09 (dd, J = 2.8, 9.0 Hz, 1H, Ar), 7.20–7.11 (m, 2H, Ar),
6.76 (d, J = 9.0 Hz, 1H, Ar), 6.71 (t, J = 7.5 Hz, 1H, Ar),
6.67– 6.61 (m, 2H, Ar), 4.84 (undivided dd, J = 5.3,
6.5 Hz, 1H, CH), 4.50 (d, J = 15.9 Hz, 1H, CHH,  H,
NH: D2O exchangeable), 4.41 (d, J = 15.9 Hz, 1H, CHH,
 H, NH: D2O exchangeable), 3.78 (s, 3H, OCH3),
2.25–1.92 (m, 2H, CH2), 1.10 (t, J = 7.4 Hz, 3H, CH3);
13C NMR (CDCl3, 101 MHz): d = 170.4 (C, C-2), 160.0
(C, C-5), 147.4 (C, C-13), 141.7 (C, C-8), 129.6 (C, C-10),
129.0 (C, C-15, C-17), 124.2 (C, C-7, C-9), 117.6 (C,
C-16), 112.8 (C, C-14, C-18), 110.7 (C, C-6), 77.3 (CH,
C-3), 52.3 (OCH3, C-1), 42.8 (CH2, C-12), 25.7 (CH2CH3,
C-4), 9.2 (CH2CH3, C-4); GCMS m/z 344 [M]
? (90), 285
(5), 243 (100), 227 (12), 197 (20), 180 (5), 167 (8), 152
(14), 134 (7), 106 (20) 93 (14), 77 (14), 59 (18); Anal.
Calcd for C18H20N2O5: C, 62.78; H, 5.85; N, 8.13. Found:
C, 62.65; H, 5.87; N, 8.26. 4aHCl a white solid mp.
106–108 C.
Methyl 2-(4-nitro-2-((phenylamino)methyl)phenoxy)pen-
tanoate (4b) Yellow solid (MeOH) This compound (4b)
was prepared from methyl 2-(4-nitro-2-((phenylim-
ino)methyl)phenoxy)pentanoate (3b) (0.56 mmol, 0.20 g)
and sodium triacetoxyborohydride (0.84 mmol, 0.178 g)
according to the general procedure. The product obtained
as a pale yellow solid was purified from methanol. 0.12 g
(60 %); mp 74–76 C; FTIR (neat) mmax: 3408, 3075, 2979,
1751, 1593, 1513, 1328, 1209, 1079 cm-1; 1H NMR
(CDCl3, 400 MHz): d = 8.25 (d, J = 2.7 Hz, 1H, Ar),
8.10 (dd, J = 2.7, 9.0 Hz, 1H, Ar), 7.20–7.14 (m, 2H, Ar),
6.76 (d, J = 9.1 Hz, 1H, Ar), 6.72 (t, J = 7.3 Hz, 1H, Ar),
6.67–6.62 (m, 2H, Ar), 4.872 (dd, J = 7.2, 5.0 Hz, 1H,
CH), 4.50 (d, J = 16.0 Hz, 1H, CHH), 4.41 (d,
J = 16.0 Hz, 2H; 1H, CHH, 1H NH: D2O exchangeable),
3.77 (s, 3H, OCH3), 2.11–1.94 (m, 2H, CH2), 1.56 (sext,
J = 7.5 Hz, 2H, CH2), 0.99 (t, J = 7.4 Hz, 3H, CH3);
13C
NMR (CDCl3, 101 MHz): d = 171.0 (C, C-2), 160.3 (C,
C-5), 147.7 (C, C-13), 142.00 (C, C-8), 129.9 (C, C-10),
129.3 (C, C-15, C-17), 124.5 (C, C-7, C-9), 117.9 (C,
C-16), 113.1 (C, C-14, C-18), 110.9 (C, C-6), 76.5 (CH,
C-3), 52.2 (OCH3, C-1), 43.1 (CH2, C-12), 34.5 (CH2-
CH2CH3, C-4), 18.5 (CH2CH2CH3, C-4), 13.7 (CH2CH2-
CH3, C-4); GCMS m/z 358 [M]
? (93), 329 (8), 299 (6),
243 (100), 227 (11), 197 (19), 167 (7), 152 (10), 106 (15),
93 (14), 77 (9), 55 (9); FTIR (cm-1): 3408, 3110–3018,
2958–2871, 1751, 1593, 1513, 1328, 1209, 1079–1059;
Anal. Calcd for C19H22N2O5: C, 66.04; H, 5.85; N, 8.56.
Found: C, 66.80; H, 5.72; N, 8.80. 4bHCl a white solid
mp. 106–108 C.
Methyl 2-(4-nitro-2-((phenylamino)methyl)phenoxy)hex-
anoate (4c) Yellow solid (MeOH) This compound (4c)
was prepared from methyl 2-(4-nitro-2-((phenylim-
ino)methyl)phenoxy)hexanoate (3c) (0.54 mmol, 0.20 g)
and sodium triacetoxyborohydride (0.81 mmol, 0.171 g)
according to the general procedure. The product obtained
as a pale yellow solid was purified from methanol. 0.11 g
(55 %); mp 42–44 C; FTIR (neat) mmax: 3416, 3051, 2955,
1742, 1592, 1512, 1337, 1203, 1082 cm-1; 1H NMR
(CDCl3, 400 MHz): d = 8.24 (d, J = 2.7 Hz, 1H, Ar),
8.09 (dd, J = 2.7, 9.0 Hz, 1H, Ar), 7.20–7.12 (m, 2H, Ar),
6.76 (d, J = 9.0 Hz, 1H, Ar), 6.71 (t, J = 7.3 Hz, 1H, Ar),
6.64 (d, J = 8.5 Hz, 2H, Ar), 4.87 (t, J = 6.0 Hz, 1H, CH),
4.49 (d, J = 15.9 Hz, 1H, CHH), 4.41 (d, J = 15.9 Hz,
1H, CHH), 3.77 (s, 3H, OCH3), 2.08–1.98 (m, 2H, CH2),
1.57–1.45 (m, 2H, CH2), 1.45–1.32 (m, 2H, CH2), 0.92 (t,
J = 7.2 Hz, 3H, CH3);
13C NMR (CDCl3, 101 MHz):
d = 171.0 (C, C-2), 160.4 (C, C-5), 147.7 (C, C-13), 142.0
(C, C-8), 129.9 (C, C-10), 129.3 (C, C-15, C-17), 124.6 (C,
C-9), 124.5 (C, C-7), 117.9 (C, C-16), 113.1 (C, C-14,
C-18), 111.0 (C, C-6), 76.7 (CH, C-3), 52.6 (OCH3, C-1),
43.2 (CH2, C-12), 32.3 (CH2CH2CH2CH3, C-4), 27.3
(CH2CH2CH2CH3, C-4), 22.3 (CH2CH2CH2CH3, C-4),
13.8 (CH2CH2CH2CH3, C-4); GCMS m/z 372 [M]
? (90),
329 (8), 243 (100), 227 (11), 197 (17), 167 (6), 152 (8), 106
(13), 93 (15), 69 (10), 59 (6); Anal. Calcd for C20H24N2O5:
C, 64.50; H, 6.50; N, 7.52. Found: C, 64.455; H, 6.62; N,
7.55. 4cHCl a white solid mp. 106–108 C.
Methyl 2-(2-methoxy-4-nitro-6-((phenylamino)methyl)phe-
noxy)butanoate (4d) Yellow solid (MeOH) This com-
pound (4d) was prepared from methyl 2-(2-methoxy-
4-nitro-6-((phenylimino)methyl)phenoxy)butanoate (3d)
(0.54 mmol, 0.20 g) and sodium triacetoxyborohydride
(0.81 mmol, 0.171 g) according to the general procedure.
The product obtained as a pale yellow solid was purified
from methanol. 0.11 g (55 %); mp 117–119 C; FTIR
(neat) mmax: 3387, 3051, 2955, 1743, 1601, 1514, 1332,
1204, 1091 cm-1; 1H NMR (CDCl3, 400 MHz): d = 7.93
(d, J = 2.6 Hz, 1H, Ar), 7.69 (d, J = 2.6 Hz, 1H, Ar),
7.20–7.11 (m, 2H, Ar), 6.74–6.68 (m, 1H, Ar), 6.67–6.60
(m, 2H, Ar), 5.26 (undivided dd, J = 5.6, 6.8 Hz, 1H, CH),
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4.57 (d, J = 16.0 Hz, 1H, CHH), 4.48 (d, J = 16.0 Hz,
1H, CHH), 4.38 (s, 1H, NH: D2O exchangeable), 3.89 (s,
3H, OCH3), 3.73 (s, 3H, OCH3), 2.10–1.92 (m, 2H, CH2),
1.08 (t, J = 7.4 Hz, 3H, CH3);
13C NMR (CDCl3,
101 MHz): d = 171.8 (C, C-2), 150.5 (C, C-6), 149.8 (C,
C-5), 147.8 (C, C-13), 143.0 (C, C-8), 133.7 (C, C-10),
129.3 (C, C-15, C-17), 117.8 (C, C-16), 116.8 (C, C-9),
113.0 (C, C-14, C-18), 107.0 (C, C-7), 80.6 (CH, C-3), 56.2
(OCH3, C-11), 52.1 (OCH3, C-1), 43.4 (CH2, C-12), 26.7
(CH2CH3, C-4), 9.3 (CH2CH3, C-4); GCMS m/z 374 [M]
?
(62), 273 (100), 257 (37), 227 (16), 207 (7), 182 (12), 154
(7), 134 (7), 106 (17), 93 (26), 77 (12), 59 (14); Anal.
Calcd for C19H22N2O6: C, 60.95; H, 5.92; N, 7.48. Found:
C, 61.05; H, 5.99; N, 7.42. 4dHCl a white solid mp.
106–108 C.
Methyl 2-(2-methoxy-4-nitro-6-((phenylamino)methyl)phe-
noxy)pentanoate (4e) Yellow solid (MeOH) This com-
pound (4e) was prepared from methyl 2-(2-methoxy-4-
nitro-6-((phenylimino)methyl)phenoxy)pentanoate (3e)
(0.52 mmol, 0.20 g) and sodium triacetoxyborohydride
(0.78 mmol, 0.166 g) according to the general procedure.
The product obtained as a pale yellow solid was purified
from methanol. 0.11 g (55 %), mp 112–114 C; FTIR
(neat) mmax: 3397, 3051, 2955, 1746, 1602, 1514, 1336,
1203, 1097 cm-1; 1H NMR (CDCl3, 400 MHz): d = 7.93
(d, J = 2.5 Hz, 1H, Ar), 7.68 (d, J = 2.5 Hz, 1H, Ar),
7.20–7.13 (m, 2H, Ar), 6.76–6.58 (m, 1H, Ar), 6.67–6.58
(m, 2H, Ar), 5.31 (t, J = 6.0 Hz, 1H, CH), 4.59 (d,
J = 15.9 Hz, 1H, CHH), 4.55 (d, J = 15.9 Hz, 1H, CHH),
4.37 (bs, 1H, NH: D2O exchangeable), 3.89 (s, 3H, OCH3),
3.72 (s, 3H, OCH3), 2.03–1.88 (m, 2H, CH2), 1.66–1.43
(m, 2H, CH2), 0.97 (t, J = 7.4 Hz, 3H, CH3);
13C NMR
(CDCl3, 101 MHz): d = 172.0 (C, C-2), 150.5 (C, C-6),
149.7 (C, C-5), 147.8 (C, C-13), 143.0 (C, C-8), 133.7 (C,
C-10), 129.3 (C, C-15, C-17), 117.8 (C, C-16), 116.8 (C,
C-9), 113.0 (C, C-14, C-18), 107.0 (C, C-7), 79.4 (CH,
C-3), 56.2 (OCH3, C-11), 52.1 (OCH3, C-1), 43.4 (CH2,
C-12), 35.4 (CH2CH2CH3, C-4), 18.3 (CH2CH2CH3, C-4),
13.8 (CH2CH2CH3, C-4); GCMS 388 m/z [M]
? (52), 273
(100), 257 (33), 227 (14), 207 (9), 182 (10), 148 (6), 106
(15), 93 (29), 87 (5), 77 (11), 73 (7), 59 (8), 55 (12); Anal.
Calcd for C20H24N2O6: C, 61.84; H, 6.23; N, 7.21. Found:
C, 61.65; H, 6.28; N, 7.15. 4eHCl a white solid mp.
106–108 C.
Methyl 2-(2-methoxy-4-nitro-6-((phenylamino)methyl)phe-
noxy)hexanoate (4f) Yellow solid (MeOH) This com-
pound (4f) was prepared from methyl 2-(2-methoxy-4-
nitro-6-((phenylimino)methyl)phenoxy)hexanoate (3f)
(0.50 mmol, 0.20 g) and sodium triacetoxyborohydride
(0.75 mmol, 0.16 g) according to the general procedure.
The product obtained as a pale yellow solid was purified
from methanol. 0.15 g (85 %); mp 119–121 C; FTIR
(neat) mmax: 3385, 3091, 2953, 1746, 1601, 1514, 1334,
1202, 1095 cm-1; 1H NMR (CDCl3, 400 MHz): d = 7.92
(d, J = 2.6 Hz, 1H, Ar), 7.68 (d, J = 2.6 Hz, 1H, Ar),
7.20–7.11 (m, 2H, Ar), 6.70 (t, J = 7.3 Hz, 1H, Ar), 6.63
(d, J = 7.8 Hz, 2H, Ar), 5.29 (undivided dd, J = 5.6,
6.8 Hz, 1H, CH), 4.56 (d, J = 15.8 Hz, 1H, CHH), 4.47 (d,
J = 15.9 Hz, 1H, CHH), 4.36 (bs, 1H, NH: D2O
exchangeable), 3.88 (s, 3H, OCH3), 3.72 (s, 3H, OCH3),
2.02–1.89 (m, 2H, CH2), 1.55–1.30 (m, 4H, C2H4), 0.90 (t,
J = 7.2 Hz, 3H, CH3);
13C NMR (CDCl3, 101 MHz):
d = 172.0 (C, C-2), 150.5 (C, C-6), 149.8 (C, C-5), 147.8
(C, C-13), 143.0 (C, C-8), 133.7 (C, C-10), 129.3 (C, C-15,
C-17), 117.8 (C, C-16), 116.8 (C, C-9), 113.0 (C, C-14,
C-18), 107.0 (C, C-7), 79.7 (CH, C-3), 56.2 (OCH3, C-11),
52.1 (OCH3, C-1), 43.4 (CH2, C-12), 33.1 (CH2CH2CH2-
CH3, C-4), 27.0 (CH2CH2CH2CH3, C-4), 22.4 (CH2CH2-
CH2CH3, C-4), 13.9 (CH2CH2CH2CH3, C-4); GCMS
402 m/z [M]? (46), 273 (100), 257 (32), 227 (13), 182 (9),
154 (5), 106 (12), 93 (25), 69 (9), 55 (6); Anal. Calcd for
C21H26N2O6 (402.18): C, 62.67; H, 6.51; N, 6.96. Found:
C, 62.72; H, 6.45; N, 6.90. 4fHCl a white solid mp.
106–108 C.
Direct reductive amination of 1a–f; synthesis of
(4a–f)
Aniline (1.87 mmol), sodium triacetoxyborohydride
(2.81 mmol), and acetic acid (0.2 mL) were added to a
mixture of methyl 2-(2-formyl-4-nitrophenoxy)alkanoate
(1a–f) (1.87 mmol) in 1,2-dichloroethane (15 mL). The
mixture was stirred magnetically at room temperature for
4 h. Next, the mixture was washed (neutralized) with an
aqueous solution of sodium carbonate 5 % (NaHCO3)
(30 mL) and extracted with ethyl acetate. The resultant
organic layer was dried and evaporated, and residue was
recrystallized from methanol to give 4a–f. Yields of
4a–f are given in Scheme 4.
General procedure for the synthesis of methyl 2-(4-
amino-2-((phenylamino)methyl)phenoxy)alkanoate
(5a and 5c–f)
A mixture of methanol (10 mL) and 10 % Pd/C catalyst
(0.033 g) was stirred magnetically under a slow stream of
hydrogen (1 bubble per second) at room temperature for
30 min. Then, a solution of 3a or 3c–f (0.91 mmol) in
methanol (10 mL) and DME (10 mL) was added, and
reduction was carried out until the conversion of 3a or 3c–
f was completed (7 h), which was determined by gas
chromatography. The mixture was left overnight, the cat-
alyst was separated on the next day, the solvent was
evaporated, and the residue was obtained to give 5a and
5c–f.
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Methyl 2-(4-amino-2-((phenylamino)methyl)phenoxy)bu-
tanoate (5a) Brown semi-solid This compound (5a)
was prepared from methyl 2-(4-nitro-2-((phenylim-
ino)methyl)phenoxy)butanoate (3a) (0.91 mmol, 0.31 g)
and 10 % Pd/C catalyst (0.031 g) according to the general
procedure. The product obtained as a brown semi-solid
0243 g (85 %); FTIR (neat) mmax: 3365, 3019, 2935, 1736,
1599, 1202, 1058 cm-1; 1H NMR (CDCl3, 400 MHz):
d = 7.18–7.09 (m, 2H, Ar), 6.72–6.54 (m, 5H, Ar), 6.46
(dd, J = 2.7, 8.5 Hz, 1H, Ar), 4.59 (t, J = 6.0 Hz, 1H,
CH), 4.36 (d, J = 14.6 Hz, 1H, CHH), 4.26 (d,
J = 14.6 Hz, 1H, CHH), 3.90–3.53 (m, 5H; 3H, OCH3, 2H
NH2: D2O exchangeable), 2.01–1.91 (m, 2H, CH2), 1.04 (t,
J = 7.4 Hz, 3H, CH3);
13C NMR (CDCl3, 101 MHz):
d = 172.5 (C, C-2), 148.6 (C, C-5), 148.5 (C, C-13), 140.7
(C, C-8), 129.4 (C, C-10), 129.1 (C, C-15, C-17), 117.2 (C,
C-16), 116.7 (C, C-9), 114.2 (C, C-7), 113.2 (C, C-6),
113.1 (C, C-14, C-18), 77.9 (CH, C-3), 52.1 (OCH3, C-1),
43.7 (CH2, C-12), 26.3 (CH2CH3, C-4), 9.6 (CH2CH3,
C-4); GCMS 314 m/z [M]? (100), 213 (46), 196 (30), 162
(36) 134 (16), 122 (59), 106 (11), 104 (25), 93 (24), 77
(18), 59 (9); Anal. Calcd for C18H22N2O3: C, 68.77; H,
7.05; N, 8.91. Found: C, 68.64; H, 7.15; N, 8.95.
Methyl 2-(4-amino-2-((phenylamino)methyl)phenoxy)hex-
anoate (5c) Brown semi-solid This compound (5c)
was prepared from methyl 2-(4-nitro-2-((phenylim-
ino)methyl)phenoxy)hexanoate (3c) (0.54 mmol, 0.20 g)
and 10 % Pd/C catalyst (0.02 g) according to the general
procedure. The product obtained as a brown semi-solid
0.151 g (82 %); FTIR (neat) mmax: 3365, 3019, 2935, 1738,
1600, 1201, 1063 cm-1; 1H NMR (CDCl3, 400 MHz):
d = 7.19–7.10 (m, 2H, Ar), 6.72–6.54 (m, 5H, Ar), 6.46
(dd, J = 2.8, 8.5 Hz, 1H, Ar), 4.63 (undivided dd, J = 5.6,
6.8 Hz, 1H, CH), 4.35 (d, J = 14.5 Hz, 1H, CHH), 4.26 (d,
J = 14.5 Hz, 1H, CHH), 3.71 (s, 4H; 3H, OCH3, 1H NH:
D2O exchangeable), 1.98–1.87 (m, 2H, CH2), 1.51–1.41
(m, 2H, CH2), 1.40–1.27 (m, 2H, CH2), 0.88 (t,
J = 7.2 Hz, 3H, CH3);
13C NMR (CDCl3, 101 MHz):
d = 172.8 (C, C-2), 148.6 (C, C-5), 148.6 (C, C-13), 140.7
(C, C-8), 129.4 (C, C-10), 129.1 (C, C-15, C-17), 117.2 (C,
C-16), 116.7 (C, C-9), 114.2 (C, C-7), 113.2 (C, C-6),
113.1 (C, C-14, C-18), 76.9 (CH, C-3), 52.1 (OCH3, C-1),
43.7 (CH2, C-12), 32.7 (CH2CH2CH2CH3, C-4), 27.4
(CH2CH2CH2CH3, C-4), 22.4 (CH2CH2CH2CH3, C-4),
13.9 (CH2CH2CH2CH3, C-4); GCMS 342 m/z [M]
? (100),
213 (63), 196 (35), 162 (9), 134 (7), 122 (49), 106 (11), 104
(26), 93 (27), 77 (17), 55 (7); Anal. Calcd for C20H26N2O3:
C, 70.15; H, 7.65; N, 8.18. Found: C, 70.35; H, 7.72; N,
8.16.
Methyl 2-(4-amino-2-methoxy-6-((phenylamino)methyl)-
phenoxy)butanoate (5d) Brown semi-solid This com-
pound (5d) was prepared from methyl 2-(2-methoxy-4-
nitro-6-((phenylimino)methyl)phenoxy)butanoate (3d)
(0.54 mmol, 0.20 g) and 10 % Pd/C catalyst (0.02 g)
according to the general procedure. The product obtained
as a brown semi-solid 0.132 g (71 %); FTIR (neat) mmax:
3365, 3019, 2935, 1737, 1599, 1199, 1054 cm-1; 1H NMR
(CDCl3, 400 MHz): d = 7.28–6.99 (m, 2H, Ar); 6.81–6.57
(m, 3H, Ar), 6.24 (d, J = 2.5 Hz, 1H, Ar), 6.13 (d,
J = 2.5 Hz, 1H, Ar), 4.72–4.66 (m, 1H, CH), 4.51–4.29
(m, 2H, CH2), 3.76–3.54 (m, 8H; 6H OCH3, 2H NH2: D2O
exchangeable), 2.03-1.83 (m, 2H, CH2), 1.08–0.83 (m, 4H,
3H CH3, 1H NH);
13C NMR (CDCl3, 101 MHz):
d = 172.8 (C, C-2), 152.1 (C, C-6), 148.5 (C, C-13), 142.8
(C, C-8), 137.3 (C, C-5), 133.5 (C, C-10), 129.1 (C, C-15,
C-17), 117.1 (C, C-16), 112.9 (C, C-14, C-18), 106.8 (C,
C-9), 99.2 (C, C-7), 81.6 (CH, C-3), 55.6 (OCH3, C-11),
51.7 (OCH3, C-1), 43.4 (CH2, C-12), 26.5 (CH2CH3, C-4),
9.2 (CH2CH3, C-4); Anal. Calcd for C19H24N2O4: C, 66.26;
H, 7.02; N, 8.13. Found: C, 66.36; H, 7.14; N, 8.23.
Methyl 2-(4-amino-2-methoxy-6-((phenylamino)methyl)
phenoxy)pentanoate (5e) Brown semi-solid This com-
pound (5e) was prepared from methyl 2-(2-methoxy-
4-nitro-6-((phenylimino)methyl)phenoxy)pentanoate (3e)
(0.93 mmol, 0.36 g) and 10 % Pd/C catalyst (0.036 g)
according to the general procedure. The product obtained
as a brown semi-solid 0.28 g (84 %); FTIR (neat) mmax:
3370, 3048, 2956, 1739, 1599, 1198, 1057 cm-1; 1H NMR
(CDCl3, 400 MHz): d = 7.27–7.02 (m, 2H, Ar), 6.71–6.57
(m, 3H, Ar), 6.24 (d, J = 2.5 Hz, 1H,Ar), 6.12 (d,
J = 2.5 Hz, 1H, Ar), 4.74 (t, J = 6.2 Hz, 1H, CH),
4.43–4.32 (m, 2H, CH2), 3.78–3.63 (m, 8H; 6H, OCH3, 2H,
NH2: D2O exchangeable), 2.10–1.73 (m, 2H, CH2),
1.73–1.35 (m, 2H, CH2), 1.06–0.78 (m, 4H; 3H, CH3, 1H,
NH: D2O exchangeable);
13C NMR (CDCl3, 101 MHz):
d = 173.0 (C, C-2), 152.1 (C, C-6), 148.5 (C, C-13), 142.8
(C, C-8), 137.2 (C, C-5), 133.5 (C, C-10), 129.1 (C, C-15,
C-17), 117.1 (C, C-16), 112.9 (C, C-14, C-18), 106.8 (C,
C-9), 99.2 (C, C-7), 80.3 (CH, C-3), 55.6 (OCH3, C-11),
51.7 (OCH3, C-1), 43.4 (CH2, C-12), 35.4 (CH2CH2CH3,
C-4), 18.1 (CH2CH2CH3, C-4), 13.9 (CH2CH2CH3, C-4);.
Anal. Calcd for C20H26N2O4: C, 67.02; H, 7.31; N, 7.82.
Found: C, 67.12; H, 7.37; N, 7.76.
Methyl 2-(4-amino-2-methoxy-6-((phenylamino)methyl)-
phenoxy)hexanoate (5f) Brown semi-solid This com-
pound (5f) was prepared from methyl 2-(2-methoxy-
4-nitro-6-((phenylimino)methyl)phenoxy)hexanoate (3f)
(0.40 mmol, 0.16 g) and 10 % Pd/C catalyst (0.016 g)
according to the general procedure. The product obtained
as a brown semi-solid 0.11 g (74 %); FTIR (neat) mmax:
3370, 3048, 2956, 1740, 1599, 1196, 1055 cm-1; 1H NMR
(CDCl3, 400 MHz): d = 7.27–6.96 (m, 2H, Ar), 6.87–6.55
(m, 3H, Ar), 6.24 (d, J = 2.5 Hz, 1H, Ar), 6.13 (d,
J = 2.5 Hz, 1H, Ar), 4.73 (t, J = 6.2 Hz, 1H, CH),
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4.40–4.29 (m, 2H, CH2), 3.83–3.62 (m, 8H; 6H, OCH3, 2H,
NH2: D2O exchangeable), 1.98–1.81 (m, 2H, CH2),
1.51–1.21 (m, 5H; 4H, C2H4, 1H, NH: D2O exchangeable),
0.87 (t, J = 7.1 Hz, 3H; CH3);
13C NMR (CDCl3,
101 MHz): d = 173.0 (C, C-2), 152.1 (C, C-6), 148.6 (C,
C-13), 142.8 (C, C-8), 137.3 (C, C-5), 133.5 (C, C-10),
129.1 (C, C-15, C-17), 117.1 (C, C-16), 112.9 (C, C-14,
C-18), 106.9 (C, C-9), 99.3 (C, C-7), 80.5 (CH, C-3), 55.6
(OCH3, C-11), 51.7 (OCH3, C-1), 43.4 (CH2, C-12), 33.1
(CH2CH2CH2CH3, C-4), 26.9 (CH2CH2CH2CH3, C-4),
22.5 (CH2CH2CH2CH3, C-4), 13.9 (CH2CH2CH2CH3,
C-4); Anal. Calcd for C21H28N2O4 (372.2): C, 67.72; H,
7.58; N, 7.52. Found: C, 67.68; H, 7.49; N, 7.51.
Microbiological work
Microorganisms
The antimicrobial activity of the synthesized compounds
was assessed against 11 microbial strains: 5 Gram-nega-
tive, Escherichia coli American Type Culture Collection
(ATTC) 25922, Escherichia coli (ATCC 8739), Pseu-
domonas aeruginosa (ATCC 27853), Pseudomonas
aeruginosa (wild-type strain isolated from clinical sample),
Acinetobacter baumannii (wild-type strain isolated from
clinical sample), and 6 Gram-positive, Enterococcus fae-
calis (ATCC 29212), Staphylococcus aureus MSSA
(ATCC 25923), Staphylococcus aureus MRSA (ATCC
43300), Staphylococcus aureus MLSB of inducible phe-
notype with resistance to macrolide–lincosamide–strep-
togramin B antibiotics (wild-type strain isolated from
clinical sample), Micrococcus luteus Polish Collection of
Microorganisms (PCM) 1944, Streptococcus mutans (wild-
type strain isolated from dental plaque). Bacterial strains
were cultivated in Brain Heart Infusion (BHI, Oxoid)
medium at 37 C for 24 h. After incubation, microbial
suspension was diluted with sterile phosphate-buffered
saline (PBS) to 108 CFU/mL (turbidity = McFarland bar-
ium sulfate standard 0.5).
Agar diffusion disk method
The antimicrobial activities of synthesized compounds
were determined by disk diffusion method as recom-
mended by National Committee for Clinical Laboratory
Standards (NCCLS) (Furtado and Medeiros, 1980). The
compounds were evaluated for antimicrobial activity
against bacteria on Mu¨eller-Hinton Agar (MHA, Oxoid)
medium. The sterile 6-mm filter paper disks (Whatman, no.
2, Sigma-Aldrich) were impregnated with 10 lL of the
tested compound at concentration 100 mg/mL in acetone
(POCH) or DMSO (Sigma-Aldrich). The concentration of
each tested compound on a disk was 10 mg/mL. The disks
were allowed to remain at room temperature until complete
diluent evaporation. The disks loaded with tested com-
pounds were placed onto the surface of the proper agar
medium (MHA) seeded with the suspension of appropriate
test microorganism and incubated for 24 h at 36 C. The
solvent acetone or DMSO was used as a vehicle control.
Commercial antibiotic ciprofloxacin (5 mg) (Oxoid) was
used as a positive control. The average diameters of the
zone of inhibition (in mm) were calculated for each tested
sample and control. Tests were performed in triplicate.
Minimal inhibitory concentration (MIC) assay
Compounds that exhibited activity against specific species
of bacteria, as determined by the agar diffusion disk
method, were further evaluated for their minimal inhibitory
concentrations (MIC) using the serial dilution technique.
Minimal inhibitory concentrations (MICs) were obtained
by measuring the areas of the microbial growth inhibition
using the bioautographic assay as described below. Prior to
this study, compounds were dissolved in DMSO to make a
300 mg/mL stock and then diluted to 200, 100, 50, 25, 10,
5 and 1 mg/mL. MIC values were defined as the lowest
concentration of each compound that completely inhibited
microbial growth. The results were expressed in milligrams
per milliliter.
Bioautographic assay
The bioautographic assay was performed as described by
(Valgas et al., 2007). Plates of silica gel (0.2 mm, Sigma-
Aldrich) were seeded in dot blot with 10 lL of each
compound at concentration 100 mg/mL in acetone (POCH)
or DMSO (Sigma-Aldrich). The concentration of each
tested compound in a spot was 10 mg/mL. Sample spots
were placed with a micropipette, and the spot diameter was
approximately 7 mm. Each sample spot was located
approximately 3 cm apart and away from the edge of TLC
plate. As positive control, a solution of 2 mg of chloram-
phenicol (Fluka) dissolved in 1 mL of DMSO (Sigma-
Aldrich) was used. As a vehicle control, the solvent ace-
tone or DMSO was used. The controls were applied to
plates in the same fashion as tested compounds. The TLC
plates were air-dried, covered with MHA (10 mL of the
medium on 9 cm diameter Petri plats) containing 100 mL
of test microorganism suspensions, and incubated for 24 h
at 36 C. After incubation, in order to visualize zones of
growth inhibition, 2 mL of MTT solution (1 mg of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide in
one mL sterile physiological solution, Sigma-Aldrich) was
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added to each Petri plate and incubation was continued for
3 h at the same culture condition. In the last step, the areas
of growth inhibition were measured for each tested com-
pound and controls and the average diameters of the zone
of inhibition (in mm) were calculated. Tests were per-
formed in triplicate.
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